Christopher Anzalone, president and CEO of Arrowhead Pharmaceuticals, Inc. is moving the company into its next stage of growth – and it is not the first time he is doing so.
When he joined the Pasadena, California-based company in 2007, he insisted on changing the company’s business model. At the time,...


![[Test]With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space](https://web.insights.norstella-labs.com/resizer/v2/G3M6E2FVDNOJPCEXELJNOIKH64.jpg?smart=true&auth=b5d5c6477bcbd6c122699f47191cbafe560695783f500a6e7b10c4d270965bdc&width=400&height=225)


